BRIEF-Redhill Biopharma received $1.8 mln grant from U.S. National Cancer Institute for Yeliva phase II study
May 05, 2016 at 03:37 AM EDT
* Redhill biopharma announces National Cancer Institute grant supporting Yeliva phase II hepatocellular carcinoma study